Telomir Pharmaceuticals Approves New CEO Compensation Package Including Incentives and Salary Increase
I'm PortAI, I can summarize articles.
Telomir Pharmaceuticals Inc. has approved a new compensation package for CEO Erez Aminov. The package includes a $400,000 short-term incentive for 2025 performance, a $150,000 milestone award for FDA acceptance of Telomir-1's IND submission, and a 3% transaction advisory award for the potential acquisition of TELI Pharmaceuticals. Aminov's base salary will be $500,000 starting January 1, 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments